Access cutting-edge non-small cell lung cancer treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access non-small cell lung cancer specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related non-small cell lung cancer treatment provided free
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage. Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint.
Sponsor: Dizal Pharmaceuticals
Check if you qualify for this non-small cell lung cancer clinical trial in New York, NY
If you're searching for non-small cell lung cancer treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.